Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE (1.62%), DAX (2.32%), CAC40 (1.66%)

Apr 03 ,2025

  • Synopsis

    • European equity markets are set to open sharply lower following President Trump's 'Liberation Day' tariff announcement. Asian equities under pressure Thursday. Japan underperforming region. Hang Seng leading China markets lower. Vietnam leading SE Asian market declines. Australia and Korea pared losses. US contracts sharply lower afterhours. Bonds rallying with Treasury, JGB and Australian yields seeing large declines. Dollar extending losses against majors, stronger on Asia and EM crosses. Crude and base metals selling off alongside equities. Gold flat. Bitcoin selling off.

    • On today's agenda, first EU-Central Asia summit, with EU's von der Leyen and Costa meeting with heads of State from Uzbekistan, Kazakhstan, others. EU's Dombrovskis participates in the EU-Türkiye High-Level Economic Dialogue in Brussels whilst EU's Šuica delivers a speech at the Parliamentary Assembly of the Union for the Mediterranean and EU's Serafin is in Helsinki (through Fri) and meets with Finland's PM Orpo. NATO foreign ministers' meeting (through Fri). In other events, SUERF event at 10:30CET, Is Europe Prepared for Extreme Events? Risks - resilience - policy responses and Montel's German Energy Day 2025. Also in Germany, Chancellor Scholz hosts King Abdullah II of Jordan, press statements are planned afterward. Later, the Chancellor travels to Madrid for bilateral talks over dinner with Spanish PM Sánchez.

    • In central banks, ECB's de Guindos speech at 9:20CET at event organised by International Federation of Accountants Forum. Riksbank's Thedéen panellist at 11:45CET at conf on how capital markets in the EU can be developed to meet investment needs and help strengthen Europe's competitiveness, co-hosted by Confederation of Swedish Enterprise. ECB's Schnabel lecture at 12noonCET at OECD's "The Lectures of the Governor" Seminar. SNB's Tschudin speaks at 10:30CET at Finanz 25. Latvia central bank's Kazāks meets with country's President Rinkēvičs. Minutes of ECB's last MPC meeting published.

    • Macroeconomic data due today include: Italy, Spain, Sweden Mar services PMI and final reads for Eurozone, France, Germany, UK, Switzerland Mar CPI, Eurozone Feb PPI

    • In corporate news, Aperam (APAM.NA) maintains Q1 guidance as per 7-Feb update and sees Q1 adj EBITDA lower than Q4. Montana Aerospace (AERO.SW) released final FY numbers. AEVIS VICTORIA (AEVS.SW) is also out with FY earings. GRENKE (GLJ.GR) reports Q1 leasing new business €740.6M vs year-ago €669.8M and agrees sale of the factoring business. Further on M&A front, Siemens (SIE.GR) confirmed acquisition of Dotmatics for $5.1B.

    • CMD/events: Deutsche Post (DHL.GR), KBC Group (KBC.BB)

  • Politics/Macro/World News

    • EU Vows to Respond With Countermeasures to Trump's 20% Tariffs - Bloomberg

    • UK Business Closures Spike Before Rises in Tax and Minimum Wage - Bloomberg

    • US to set tariffs in three separate bands of 10%, 15%, and 20%, to differ by country and industry - Sky News

    • EU and Nato ministers meet to redraw European security map - FT

    • Trump piles on the tariffs but UK escapes the worst - The Times

  • Top company news

    • Earnings/updates

      • PROX.BB (Proximus) -- sells to Nextensa its two office towers and the development of its new headquarters for €62.5M

      • NANO.FP (Nanobiotix) -- reports FY net income (€68.1M) vs FactSet (€47.6M) [8 est, (€54.3)-(35.7M)]

      • CYAD.BB (Celyad Oncology) -- reports FY net income (€5.8M) vs year-ago (€8.5M)

      • APAM.NA (Aperam) -- maintains Q1 guidance as per 7-Feb update; sees Q1 adj EBITDA lower than Q4

      • AEVS.SW (AEVIS VICTORIA)-- reports FY EPS (CHF0.03) vs year-ago (CHF0.46)

      • GLJ.GR (GRENKE) -- reports Q1 leasing new business €740.6M vs year-ago €669.8M; agrees sale of the factoring business

      • AERO.SW (Montana Aerospace) -- reports final FY earnings: FY net income attributable €36.1M vs FactSet €24.2M [5 est, (€0.0)-49M]

    • M&A

      • SIE.GR (Siemens AG) -- Siemens confirms acquisition of Dotmatics for $5.1B

      • SAF.FP (Safran) -- EU set to greenlight Safran's $1.8B Collins deal -- Reuters

      • OR.FP (L'Oreal) -- SalonCentric Canada, a subsidiary of L'Oréal Canada, signs agreement to purchase all assets of CONCEPT JP; price not disclosed

      • HOLN.SW (Holcim) -- acquires Peruvian producer of specialty building solutions Compañía Minera Luren

      • DSFIR.NA (DSM-Firmenich) -- DSM-Firmenich's animal nutrition and health unit reportedly sees interest from private equity bidders -- Bloomberg

      • DSFIR.NA (DSM-Firmenich) -- increases its stake in Andre Pectin to 90.5%; financial details not disclosed

      • PSM.GR (ProSiebenSat.1 Media) -- MFE-MEDIAFOREUROPE to offer ProSieben shareholders for each ProSieben share tendered into the voluntary public takeover offer (once made) mixed consideration consisting of €4.47 in cash and 0.4 newly-issued MFE A shares.

      • PROX.BB (Proximus) -- sells to Nextensa its two office towers and the development of its new headquarters for €62.5M

      • MTRS.SS (Munters Group) -- Munters business area FoodTech takes full ownership of MTech Systems; follows completion of previously announced transaction with minority shareholders

    • Healthcare

      • NOVN.SW (Novartis) -- receives FDA accelerated approval for Atrasentan for proteinuria reduction in primary IgAN

      • SAN.FP (Sanofi) -- issues press release on FDA's grant of orphan drug designation for rilzabrutinib for wAIHA, IgG4-RD

      • SRPT (Sarepta Therapeutics) -- Roche says EMA has requested temporary hold on studies of Elevidys -- letter (timing uncertain)

      • ROG.SW (Roche Holding) -- Genentech's Phase III Ocrevus high dose study in people with relapsing multiple sclerosis did not meet its primary endpoint

      • LONN.SW (Lonza Group) -- requests trading halt, effective immediately; news pending

      • SOBI.SS (Swedish Orphan Biovitrum) -- NICE recommends efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A

      • CRNA.NO (Circio Holding) -- Circio Holding, Entos Pharmaceuticals initiate collaboration to test novel platform for circVec circular RNA delivery

    • Other

      • NOKIA.FH (Nokia) -- Nokia's share buyback program initiated in November 2024 has been completed

      • BP.LN (BP) -- to announce today that production has started on new gasfield in Trinidad, as it seeks to calm investor nerves by boosting oil and gas production - FT

      • RR.LN (Rolls-Royce Holdings) -- Rolls-Royce in talks with UK government over subsidies to help fund £3B development of engine to power narrow-body aircraft - FT

      • ROCK.B.DC (Rockwool) -- announces 1-for-10 share split

      • AKRBP.NO (Aker BP) -- extends its alliance agreement with SLB and Stimwell Services for another five years to further accelerate and boost oil production

      • FRAS.LN (Frasers Group) -- announces further strategic investment in Hugo Boss AG

      • IMPN.SW Hochtief, Implenia JV wins contract worth somewhere in the high hundreds of millions of euros

  • Key rating changes

    • Upgrades

      • AWE.LN (Alphawave IP Group) -- to buy from hold at Jefferies

    • Downgrades

      • LEG.GR (LEG Immobilien) -- to equal weight from overweight at Barclays

      • BNP Paribas Exane downgrades HAG.GR, R3NK.GR

    • Initiations

      • GUBRA.DC (Gubra A/S) -- buy at DnB Markets

  • Data

    • Nikkei (3.32%) to 34540.09

    • Hang Seng (2.13%) to 22707.32

    • Shanghai Composite (0.55%) to 3331.57

    • S&P futures (170.5) vs prior close of 5712.3

    • €-$ +0.0094 or +0.87% to 1.0949

    • $-¥ (2.17) or (1.45%) to 147.11

    • €-¥ (1.00) or (0.62%) to 161.04

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE